Siste oppdatering :
27/11/2025
Antihistamin (H1)   Cyclizine lactate  
Injeksjon
Oppløsningsstabilitet Stabilitet i blandinger Faktorer som påvirker stabiliteten Kompatibilitet Administrasjonsmåte Referanser pdf
   Kjemisk struktur  

Handelsnavn   Handelsnavn     

Handelsnavn er veiledende og sammensetning av hjelpestoffer kan være forskjellig avhengig av land og produsent

Cyclizine lactate Storbritannia
Valoid Storbritannia
Referanser   Injeksjon   Referanser : Cyclizine lactate  
Type publikasjon
58 Journal Parker WA.
Physical compatibility of ranitidine HCl with preoperative injectable medications.
Can J Hosp Pharm 1985 ; 38: 160-161.
227 Journal Fawcett JP, Woods DJ, Munasiri B, Becket G.
Compatibility of cyclizine lactate and haloperidol lactate.
Am J Hosp Pharm 1994 ; 51: 2292.
788 Journal Regnard CFB, Mannix K.
Subcutaneous drug compatibility in palliative care.
Lancet 1989 ; 2 (8670): 1044-1045.
1230 Journal Regnard C, Pashley S, Westrope F.
Anti-emetic / diamorphine mixture compatibility in infusion pumps.
Br J Pharm Pract 1986 ; 8: 218-220.
1886 Journal Allwood MC.
The stability of diamorphine alone and in combinaison with antiemetics in plastic syringes.
Palliative Med 1991 ; 5: 330-333.
2125 Journal Gardiner PR.
Compatibility of an injectable oxycodone formulation with typical diluents, syringes, tubings, infusion bags and drugs for potential co-administration.
Hospital Pharmacist 2003 ; 10: 354-361.
2900 Journal Hines S, Pleasance S.
Compatibility of an injectable high strength oxycodone formulation with typical diluents, syringes, tubings,infusion bags and drugs for potential co-administration.
EJHP 2009 ; 15, 5: 32-38.
3374 Journal Smith R.P.R, Jones M.
Precipitation in Manchester: ketorolac/cyclizine
Anaesthesia 2001 ; 56: 494-495.
4982 Labratorium Diamorphine Hydrochloride 100mg for Injection - Summary of Product Characteristics Updated 06-May-2020.
Wockhardt UK Ltd 2020
5073 Labratorium Palladone 10 mg/ml solution for injection or infusion - Summary of Product Characteristics Updated 28-Apr-2025.
Napp Pharmaceuticals Limited 2025

  Mentions Légales